To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

And more pharma news updates from Pharmalittle.

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

The benefits from Eli Lilly’s Kisulna (donanemab) remain too small to justify the additional cost to the National Health Service (NHS), said the UK health technology assessor the National Institute ...

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

Analysts expect the positive outcome to support Eisai, the Japan-based pharmaceutical company behind lecanemab, as it works to bring the drug to market. Eisai is co-developing lecanemab with Biogen, ...